To compare perioperative factors and adverse events (AEs) in men undergoing photoselective vaporisation of the prostate (PVP) with or without continued anticoagulation therapy.
Results
There was no statistically significant difference in the overall incidence of perioperative AEs between those receiving and not receiving anticoagulation therapy (30.5% vs 19.9%, P = 0.07). However, there was a statistically significant difference in the incidence of high-grade Clavien-Dindo events in men who continued anticoagulation during PVP (P = 0.01). No men required blood transfusion. There was no difference in operative times and energy utilisation between the groups. In all, 53 of the 59 men in the anticoagulation group had a high-grade American Society of Anesthesiologists score, compared to 27 of the 272 men in the control group. The anticoagulation group were also significantly older. The anticoagulation group had a significantly longer length of hospital stay and duration of catheterisation compared to the controls.
Introduction
BPH is a common condition in older men. The LUTS associated with BPH adversely affect the quality of life of men and can be improved with medical or surgical intervention [1] . TURP is considered the 'gold standard' in the surgical treatment of BPH. However, TURP is associated with relatively high morbidity rates and bleeding is one of the main complications, occurring in 0.4-7.1% of cases [2] . In particular, men receiving anticoagulant therapy have significantly higher rates of bleeding complications associated with TURP [3] .
Photoselective vaporisation of the prostate (PVP) is an established alternate surgical intervention for BPH [4] . PVP has an advantage over TURP, due to its haemostatic properties, and has been shown to be a safe alternative treatment for patients receiving therapeutic anticoagulation. The use of the most recent technology, the 180-W lithium triborate (LBO) laser, has been justified based on the safety profile reported with the use of earlier generation lasers [5] [6] [7] [8] [9] . However, it should not be assumed that the 180-W LBO laser is equivalent to its predecessors in terms of adverse events (AEs) given that the current laser is significantly more powerful than its predecessors. There are currently no studies that have evaluated the impact of continued anticoagulation in men undergoing PVP using the 180-W LBO laser.
The primary objective of the present study was to compare perioperative factors and AEs in men undergoing PVP with the 180-W LBO laser with or without continued anticoagulation therapy.
Patients and Methods
Institutional ethics approval was granted (HREC Project ID: 2012-025). A retrospective review of a prospectively recorded database of 373 patients undergoing PVP at Sydney Adventist Hospital from July 2010 to December 2016 was undertaken. The procedure was performed under general anaesthesia. A single laser setup was used for all cases using the 180-W Greenlight XPS TM laser console and MoXy TM laser fibre (Boston Scientific, Minnetonka, MN, USA) in the standardised approach, as previously described by the International Greenlight User's Group [10] .
Three patient groups were identified. All patients taking anticoagulants continued these medications during the perioperative period. Patients who continued anticoagulation, as defined as heparin, warfarin, clopidogrel, dipyridamol and new oral anticoagulant (NOAC) medications, formed the anticoagulant limb of the study. Patients who were on aspirin exclusively, which was continued during the perioperative period in all cases, formed the aspirin group. Patients who were on neither anticoagulants nor aspirin formed the control group. Patients who were on combined treatment with both clopidogrel and aspirin were treated in this analysis as for patients on clopidogrel alone. Patients who were on combined treatment with both warfarin and aspirin were treated in this analysis as for patients on warfarin alone.
Clinical care pathways dictate routine catheter removal the next morning after surgery irrespective of a history of anticoagulation, urinary retention or prostate size. If the urine was judged to be moderately blood stained, catheter removal would be deferred until clinician review. Haemoglobin was not routinely measured after PVP, based on the the senior author's extensive experience with the 80-W potassiumtitanyl-phosphate (KTP) and 120-W LBO laser platforms, where no significant change was observed, as well as the fact that almost all patients had been discharged from hospital before the results became available.
Perioperative factors analysed included baseline IPSS and quality of life index, TRUS measured prostate volume, American Society of Anesthesiologists (ASA) physical status classification system score, operating time, laser time, and energy utilisation.
Continuous variables were reported as means (SDs), calculated using Microsoft office Excel 2010. Statistical analysis was performed using a two-sided independent t-test with an online statistical package (http://www.socscistatistics.com/te sts/Default.aspx). The Clavien-Dindo classification was used to evaluate all AEs occurring within 90 days after PVP [11] . AEs were subcategorised as low grade (Clavien-Dindo grade I-II) or high grade (Clavien-Dindo grade III-V) and analysed with Pearson's chi-square test. A P < 0.05 was considered statistically significant.
Results

Patient Characteristics
Patient characteristics are summarised in Table 1 . In all, 373 patients were included in the study. The mean (SD) age was 69.6 (9.0) years. Of the 59 patients receiving anticoagulant therapy, four subjects were on heparin, 23 on warfarin, 20 on clopidogrel, one on dipyridamol-aspirin combination, nine on NOAC medications, and two on clopidogrel-warfarin combination drugs. In all, 42 patients were taking aspirin alone. The three groups were similar in terms of body mass index. Patients on anticoagulant therapy had a higher mean age than those in the control (P < 0.001) and aspirin groups (P < 0.02). There was no significant difference between the three groups for TRUS prostate volume, PSA level, quality-of-life score and International Index of Erectile Function (IIEF) score. Patients in the aspirin group had a higher IPSS compared to the anticoagulation group (P = 0.027). In the anticoagulation group (59 men), 53 men had a high-grade ASA score, defined as ASA III or IV. In the control group (272 men) and aspirin group (42 men), 27 and 13 men had a high-grade ASA score, respectively.
In the control, anticoagulation and aspirin groups, 39 (14.3%), 15 (25.4%) and nine (21.4%) men were in urinary retention with a urethral catheter in situ, respectively. In the control group, previous BPH-related surgery had been performed in seven patients (four TURP, three PVP). In the anticoagulation and aspirin groups, a single patient in each had previously undergone a TURP.
Operative Variables
After PVP, the routine was to use a Bard Biocath TM twoway Foley catheter; however, three-way irrigation catheters were placed in four (6.7%) men in the anticoagulation group and six (2.2%) men in the control group. Other operative variables are shown in Table 2 . There were no significant differences in the total operation time, laser time and energy utilisation between the groups. The anticoagulation group had a significantly longer perioperative length of hospital stay (46.6 vs 23.1 h) and duration of catheterisation (32.4 vs 15.6 h) compared to the control group. 
Perioperative AEs
The overall complication rate was 22%, with 82 AEs reported. AEs are summarised in Tables 3 and 4 . Most of the AEs were low grade (79%), whereas the high-grade AEs comprised 21% of the total AEs. The postoperative mortality rate (ClavienDindo grade V) within 90 days of PVP was zero. The most common complication was re-catheterisation, followed by acute urinary retention. Six patients had postoperative haematuria. A significant drop in haemoglobin levels was defined as <100 g/L and was the threshold to transfuse. None of the patients required a blood transfusion. One patient on anticoagulant therapy developed sepsis and atrial fibrillation requiring cardioversion. Complication rates in the anticoagulation, aspirin and control groups were 30.5%, 23.8% and 19.9%, respectively. There was no significant difference in the overall AE rates between the anticoagulation and control groups (chi-square statistic = 3.2, P = 0.07). However, there was a significant difference between the anticoagulation and control group when comparing the number of high-grade AEs and no AEs (chi-square statistic = 10.7, P = 0.011).
Sub-Analysis of Anticoagulant Therapy AEs
For the purposes of the sub-analysis, two patients taking a combination of warfarin and clopidogrel, and one taking a combination of dipyridamole and aspirin were excluded. AEs occurring in patients on anticoagulation therapy are summarised in Tables 5 and 6 . Patients taking warfarin had higher rates of AEs (nine of 23 patients, 39%) than those taking clopidogrel (six of 20 patients, 30%) and NOACs (two of nine patients). Patients on heparin had no AEs. All three AEs classified as Clavien-Dindo grade >IV occurred in patients receiving warfarin therapy.
Discussion
The primary objective of the present study was to evaluate perioperative factors and AEs in men taking anticoagulant therapy whilst undergoing PVP. The present study is the largest study to date addressing AEs occurring in men on continued anticoagulation after treatment with PVP using the 180-W LBO laser. The findings show that there was no statistically significant difference in the overall incidence of perioperative AEs between those receiving and those not receiving anticoagulation therapy (30.5% vs 19.9%, P = 0.07). Importantly, no men required a blood transfusion and there were no thromboembolic events. This finding is supported by previously published reports demonstrating that anticoagulant use in men undergoing PVP using the 80-W and 120-W lasers is not associated with increased perioperative morbidity [5] [6] [7] [8] [9] . One study investigated a small cohort of patients undergoing PVP using the 80-W KTP laser, of which two patients were on ongoing clopidogrel, 14 on ongoing aspirin and eight on discontinued warfarin [12] . Similarly, the study found that no patients had any adverse bleeding or thromboembolic events.
Although it failed to achieve statistical significance, the magnitude of the difference in overall AEs between the anticoagulation and control groups (30.5% vs 19.9%) would be clinically significant. A difference of 10.6%, would equate to a number needed to harm of 10. With a larger sample size in the anticoagulation group, it is probable that statistical significance would have been achieved; assuming the Clavien-Dindo system Number of AEs (%)
Control (n = 272) Anticoagulation (n = 59) Aspirin (n = 42) Total (n = 373) proportion of events stayed the same. A clinically significant difference between the two groups would not have been surprising due to the significant comorbidity in the anticoagulation group. By virtue of being on an anticoagulant medication, men in this group are expected to have a greater likelihood of cardiovascular disease. Indirectly, this is reflected in the differences in the ASA scores for the two groups. As expected, most (90%) of the anticoagulation group had highgrade ASA scores. Patients on anticoagulants were significantly older than the control group and this is consistent with a recent publication by Lee et al. [13] . Older age is not surprisingly associated with increased cardiovascular and cerebrovascular comorbidities and thus an increase in anticoagulant use.
The present study did find that there was a statistically significant difference in the incidence of high-grade ClavienDindo events in men who continued anticoagulation during PVP (P = 0.01). The present study also found that the perioperative hospital length of stay (46.6 vs 23.1 h) and duration of catheterisation (32.4 vs 15.6 h) were significantly longer for the anticoagulation group compared to the control group. As discussed previously, these findings are not surprising due to the significant comorbidities of men in the anticoagulation group. This deviates from previous published reports showing that earlier generations of PVP are safe and effective in patients on anticoagulation [5] [6] [7] [8] [9] . Many of the earlier studies were limited by small sample sizes and the cessation of anticoagulation therapy during the perioperative period, which may not reflect an accurate profile of the safety of PVP in the anticoagulated patient [6, 8] . One of the few studies that continued anticoagulation therapy found that the use of aspirin, warfarin and clopidogrel was safe when undergoing PVP using the 120-W laser [14] . However, these studies did not classify AEs using the Clavien-Dindo system, which aims to eliminate subjective interpretation of AEs and creates a standardised system for reporting perioperative surgical complications [11] .
Research specifically addressing anticoagulation in the context of the 180-W LBO laser is sparse. In one retrospective study, Lee et al. [13] analysed 384 patients undergoing PVP with the 180-W LBO laser, with 146 patients on aspirin, 34 on clopidogrel, and 57 on warfarin. All patients taking clopiogrel, and 38% of those taking warfarin had their medication discontinued throughout the perioperative period [13] . The study showed that there was no difference in the rates of bleeding complications, UTIs or urinary retention when compared to patients not on anticoagulation. However, men on anticoagulation had significantly higher rates of conversion to TURP [13] . The 180-W laser has similar efficacy for patients regardless of anticoagulation, demonstrated by the similar improvement in functional outcomes including IPSS, maximum urinary flow rate and post-void residual urine volume [13] .
The only randomised controlled trial investigating the 180-W PVP showed a non-inferiority of PVP to TURP for functional outcomes and complication rates [4] . However, patients were discontinued on anticoagulant therapy preoperatively for 3-5 days and excluded if they were unable to do so. In other studies addressing the safety and efficacy of the 180-W laser, patients on anticoagulation were included in the cohort of patients, but no specific comparison was made [12, 15] . In one such study, the overall rate of AEs (38%) was higher than the present study (22%) [4] . The overall incidence of clot retention (3% vs 4%), re-catheterisation (13% vs 15%), UTI (8% vs 9%) and haematuria (6% vs 5%) were similar [4] . The main difference between the results was that in our present study there were four cases of capsular perforation, compared to none in the previous study.
The strength of the present study lies in the fact that men taking aspirin were not included within the anticoagulant group, but rather were treated as a separate group. Aspirin is well recognised to impair platelet function, but has been shown to have no impact on morbidity when continued during TURP [16] . On this basis, aspirin should not be included when analysing cohorts of patients who are on anticoagulation.
Another strength of the present study is that sub-analysis of the anticoagulant medications was performed. In our study, warfarin was the anticoagulant with the highest rate of AEs (39%) compared to other anticoagulant medications. A 2011 study using the 120-W laser reported a similar rate of AEs in men receiving ongoing warfarin therapy to the present study (35% vs 39%) [17] . In the present study, of the seven highgrade complications that occurred in the anticoagulation group, five were in patients taking warfarin and two in patients taking clopidogrel; none occurred in those taking NOACs.
The present study has a number of limitations. These include the retrospective nature of the study and the lack of randomisation of patients. Another limitation of the study is that it was a single expert surgeon, single-centre series and therefore the findings may not be generalisable.
In conclusion, while continued anticoagulation therapy is not associated with an overall increase in perioperative AEs, it is associated with an increased rate of high-grade ClavienDindo events. The findings of the present study suggest that there should be caution in extrapolating results about the safety profile of earlier generation lasers to the current 180-W LBO laser for patients on anticoagulation.
